A carregar...

Insurance Companies’ Perspectives on the Orphan Drug Pipeline

BACKGROUND: Rare diseases are of increasing concern to private and public healthcare insurance plans. Largely neglected by manufacturers before the 1983 passing of the Orphan Drug Act (ODA), orphan drugs have become a commercialization target of steadily increasing importance to the healthcare indus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Handfield, Robert, Feldstein, Josh
Formato: Artigo
Idioma:Inglês
Publicado em: Engage Healthcare Communications, LLC 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4046481/
https://ncbi.nlm.nih.gov/pubmed/24991385
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!